Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.57 |
| ▸ | CDK2 | P24941 | 5/20 | 0.57 |
| ▸ | GSK3B | P49841 | 5/20 | 0.57 |
| ▸ | CDC7 | O00311 | 4/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.57 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.57 |
| ▸ | PRKACA | P17612 | 3/20 | 0.57 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.57 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | PRKX | P51817 | 1/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4854997 | 0.91 | GSK3B (0.53) | DYRK1AKCNH2ROCK2CDK2GSK3B | |
| SCHEMBL4847983 | 0.87 | DYRK1A (0.50) | DYRK1AKCNH2ROCK2CDK2GSK3B | |
| SCHEMBL4857031 | 0.84 | CHEK1 (0.54) | DYRK1AKCNH2ROCK2CDK2GSK3B | |
| SCHEMBL4857465 | 0.83 | GSK3B (0.57) | DYRK1AKCNH2ROCK2CDK2GSK3B | |
| SCHEMBL4856972 | 0.83 | CHEK1 (0.58) | DYRK1AKCNH2ROCK2CDK2GSK3B | |
| SCHEMBL4857917 | 0.83 | IRAK4 (0.51) | DYRK1AKCNH2ROCK2CDK2GSK3B | |
| SCHEMBL4857059 | 0.82 | ROCK2 (0.50) | DYRK1AKCNH2ROCK2CDK2GSK3B | |
| SCHEMBL4850253 | 0.82 | CHEK1 (0.57) | DYRK1AKCNH2ROCK2CDK2GSK3B | |
| SCHEMBL4857470 | 0.80 | CHEK1 (0.85) | DYRK1AKCNH2ROCK2CDK2GSK3B | |
| SCHEMBL4851580 | 0.79 | CHEK1 (0.48) | DYRK1AKCNH2ROCK2CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | claimed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | DYRK1A 1117/4885KCNH2 2535/4885ROCK2 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.